Australian Pharmaceutical Industries Limited Overview
API continues to trade as Australian Pharmaceutical Industries Pty Ltd, the legal entity at the centre of the Wesfarmers Health division. It is the contracting party for subsequent acquisitions such as InstantScripts (Wesfarmers Health release, 12 June 2023) and the Infinity Pharmacy Group receivership (Priceline Pharmacy statement, December–January 2025/26).
-
API as the operating entity.
-
Wesfarmers Health as its reporting perimeter.
Where only parent-level data exist, the listed parent Wesfarmers Limited (ASX: WES) is used.
API is the operating backbone of Wesfarmers Health. It is one of Australia's three national full-line pharmaceutical wholesalers, alongside Sigma Healthcare and EBOS's Symbion, and it is also franchisor of Priceline Pharmacy, the country's largest health-and-beauty-focused pharmacy banner.
Since being absorbed by Wesfarmers in March 2022, it has evolved from a low-margin distributor with a retail arm into a multi-format health platform. The platform spans:
-
433 franchised Priceline Pharmacies and 67 company-owned Priceline/atomica stores
-
152 banner pharmacies (Soul Pattinson, Pharmacist Advice, Pharmacy 4 Less)
-
180 medical-aesthetics clinics (SILK, Clear Skincare)
-
the InstantScripts telehealth platform
-
an automated fulfilment network serving over 4,000 pharmacy customers
Revenue reached A$6.47bn in FY2026, but margins remain thin: EBT margin was 1.2% and return on capital 4.2%. The investment case is therefore a margin-mix story. Management is shifting earnings toward the higher-margin Consumer business, using Wesfarmers' data, loyalty (OnePass, Pulse Rewards) and supply-chain capabilities, while defending wholesale share against a merged Sigma–Chemist Warehouse.
What the company does
API/Wesfarmers Health runs three interlocking activities.
1. Pharmaceutical wholesale (the "Wholesale" business).
API buys prescription (PBS-listed and private) medicines, over-the-counter (OTC) products, and health, beauty and general merchandise from manufacturers. It warehouses them in a national network of fulfilment centres and delivers to community pharmacies, often more than once daily. Customers include:
-
Priceline Pharmacy franchisees
-
banner-group members
-
independent pharmacies
-
other groups such as Pharmacy 777 in Western Australia (added around 2020–21, per API CEO remarks reported by Pharmacy Daily, January 2021)
-
hospitals and other channels
API participates in the Commonwealth's Community Service Obligation (CSO) arrangements for full-line wholesalers. These require it to supply the full PBS range to any pharmacy within set timeframes, in return for a share of a government funding pool. In FY2026, wholesale growth was driven by new customer acquisitions and demand for GLP-1 weight-loss and other high-value drugs, while automation lowered supply-chain unit costs (WES FY26 Results).
2. Consumer retail and franchising (the "Consumer" business).
Sources: WES FY26 Results; Pharmacy Daily, 19 August 2026.
3. Private-label and exclusive brands.
API has long developed owned and exclusive health, personal-care and beauty lines sold mainly through Priceline. In the listed era this was reported as "Consumer Brands", which grew revenue 30.7% in FY2019 (Pharmacy Daily, FY19 results coverage). Under Wesfarmers this has extended to AestheticsRX and "differentiated beauty, skincare and private label ranges" (WES FY26 Results).
Business and revenue model
| Revenue stream | Nature | Margin profile | Disclosure |
|---|---|---|---|
| Pharmaceutical wholesale sales | Product sales (PBS medicines, OTC, front-of-shop goods) to pharmacies; CSO funding | Very low gross margin; PBS mark-ups regulated | Revenue split not separately disclosed post-2022 |
| Franchise fees, rebates and marketing levies | Service/royalty-type income from Priceline Pharmacy franchisees | Higher margin | — |
| Company store retail sales | Direct retail (Priceline, atomica) | Retail margin | — |
| Clinic services | Laser hair removal, skin treatments, injectables; service fees, memberships and packages | Higher margin | — |
| Telehealth fees | Per-consult or subscription digital health services | Higher margin, asset-light | — |
| Health station / data services | SiSU stations; partner/sponsor revenue | — | — |
| Retail media | Supplier-funded advertising across Priceline digital and physical assets | Higher margin | — |
Independent characterisation. By revenue, API remains overwhelmingly a product distributor. In FY2021, before the takeover, pharmacy distribution was roughly three-quarters of revenue (Barchart company description; API FY2020 reporting cited by Pharmacy Daily put pharmacy distribution revenue at A$2.9bn of approx. A$4.0bn).
By earnings potential and management attention, however, the Consumer business is the centre of gravity. Wesfarmers repeatedly describes its aim as "growing share and scale in the higher-margin and less capital-intensive Consumer segment and improving performance in the Wholesale segment" (Wesfarmers FY25 commentary reported by Pharmacy Daily, August 2025).
The FY2026 divisional margin, an EBT margin of 1.2%, shows that the mix shift is still at an early stage.
Value-chain position
API sits in the middle of the Australian medicines value chain:
Manufacturers / importers → full-line wholesaler (API) → community pharmacy (franchised Priceline Pharmacy, banner and independent stores) → patient/consumer
It also has vertically integrated:
-
forward positions into retail brand ownership (Priceline), clinics (SILK/Clear Skincare) and digital prescribing (InstantScripts), and
-
backward positions into private-label product development.
Australian pharmacy ownership and location rules restrict pharmacy ownership to registered pharmacists. As a result, API and Wesfarmers cannot own dispensaries directly; Priceline Pharmacy operates through franchise agreements with pharmacist owners. Wesfarmers has publicly stated its support for these rules (Wesfarmers statements at the November 2021 Scheme Implementation Deed and the March 2022 completion).
Customer types and end-markets
| Customer type | End-market |
|---|---|
| Community pharmacies (franchised, bannered, independent) | Prescription medicines (PBS), OTC medicines |
| Retail consumers | Health, beauty, personal care, cosmetics, vitamins and supplements |
| Patients (direct-to-consumer) | Telehealth consultations, e-prescriptions |
| Clinic clients | Medical aesthetics (laser, skin, injectables) |
| Suppliers / advertisers | Retail media, loyalty-linked promotions |
| Government | CSO funding, vaccination and pharmacy services programs (indirectly via pharmacies) |
Company's own description
Wesfarmers describes the division as a business that is "well positioned to continue improving earnings and returns by executing its transformation program and capitalising on trends in the large and growing health and beauty market" (WES FY26 Results, Health outlook).
At its 2023 formation review, Wesfarmers described the division as a "complementary portfolio of health, wellbeing and beauty assets that is well positioned to deliver long-term growth and capitalise on health sector tailwinds" (Wesfarmers 2023 Annual Report, as reported by Pharmacy Daily).
Strategy
Stated strategy themes (Wesfarmers FY2025–FY2026 releases, paraphrased)
-
Execute a multi-year transformation program to improve earnings and returns. Wesfarmers describes this as "gaining momentum" in FY2026.
-
Accelerate growth in the higher-margin Consumer business: Priceline network growth, value pricing on key lines, differentiated beauty/skincare/private label, digital and loyalty.
-
Build on recent improvements in Wholesale: customer acquisition, automation of fulfilment centres, investment in core technology systems.
-
Expand the addressable market through new formats: atomica, Pharmacy 4 Less, InstantScripts Pharmacy Health Hub.
-
Leverage Group capabilities: OnePass, OneData (about 12m customer records), the OneReach retail media network, AI, and the Flybuys JV.
Strategic initiatives announced or executed in the last 24 months
| Initiative | Date | Description | Status |
|---|---|---|---|
| atomica beauty format | Jan 2025 | New affordable beauty retail chain | 10 stores at 30 June 2026 |
| InstantScripts Pharmacy Health Hub | Pilot from mid-2024; expanded FY2026 | Pharmacy format integrating telehealth | 4 stores at 30 June 2026 |
| Pharmacy 4 Less acquisition | 4 Jun 2025 | Discount banner, 65 pharmacies | Integrated; named FY27 growth format |
| Telehealth Code of Practice | Jul 2025 | Clinical governance standard for telehealth | Live |
| New Priceline Pharmacy app | FY2026 | Omnichannel and loyalty integration | Live |
| MediAesthetics simplification | FY2025–FY2026 | Simplified operating model, refreshed brand identities, AestheticsRX expansion | Profitable growth in FY2026 |
| Fulfilment centre automation | FY2025–FY2027 | Cairns (operational FY26), Adelaide and Perth (FY27) | In progress |
| Infinity Pharmacy Group intervention | Dec 2025 | Receivers appointed to protect wholesale receivables and maintain network continuity | Sale process ongoing (WES FY26 Results) |
| Inventory contingency | 2H FY2026 | Higher stock to guard against Middle East supply disruption | Temporary working-capital investment |
| Pulse Rewards | Aug 2026 | Sister Club relaunched as a coalition loyalty program across Health brands | Live |
| Retail media and OnePass integration | Ongoing | Group retail media network (OneReach); OnePass benefits extended | Scaling |
| Health screening partnerships | Aug 2026 | Health Check program with SiSU stations; reported involvement of Latrobe Health Services | Details limited |
Cost programs. Productivity and automation are cited, but no quantified divisional cost-out target has been publicly disclosed.
Medium-term financial targets. Wesfarmers does not publish numerical divisional targets for Health. The qualitative guidance is to "continue improving earnings and returns". Group FY2027 net capex guidance is A$1.3–1.5bn, which includes Health supply-chain investment (WES FY26 Results).
Products & Services
Consumer — Priceline
| Offering | Description | Target customer | Launch / latest | Pricing model | Flagship / notes |
|---|---|---|---|---|---|
| Priceline Pharmacy (franchise) | Full-service community pharmacy combining dispensary with large health, beauty, cosmetics and personal-care front of shop; pharmacist services such as vaccinations, health checks and dose administration aids | Women-skewed health and beauty shoppers; prescription patients | Franchise model since the 2000s; 433 stores at 30 June 2026 | Franchise fees and wholesale supply; retail pricing set by franchisees with API promotions | FY2026 headline network sales +12.7% incl. dispensary; 1H FY26 +14.4%; FY25 +11.9% (WES releases; Pharmacy Daily) |
| Priceline (company-owned) | Non-pharmacy health and beauty stores | Beauty and personal-care shoppers | 67 stores incl. atomica at 30 June 2026, down from 89 in 2022 | Retail | Network rationalised since COVID-era closures |
| atomica | Affordable, accessible beauty-focused retail format | Value-seeking beauty shoppers | Launched January 2025; 10 stores at 30 June 2026 | Retail | Positioned as an addressable-market expansion format (WES FY26 Results) |
| Pharmacy 4 Less | Discount pharmacy banner | Price-sensitive shoppers | Acquired 4 June 2025 (53 franchised pharmacies plus 12 Your Chemist Shop) | Banner/franchise | Named as a new-format growth lever in FY27 outlook |
| Soul Pattinson Chemist | Banner for independent pharmacies | Independent pharmacy owners and their patients | Legacy API banner | Banner membership | Included in 152 banner pharmacies |
| Pharmacist Advice | Banner/marketing program for independents | Independent pharmacies | Legacy API banner | Banner membership | Included in 152 banner pharmacies |
| Club Premium | Independent pharmacy support program (historic) | Independents | Legacy | Program membership | Cited in API's listed-era reporting |
| InstantScripts Pharmacy Health Hub | Pharmacy format integrating telehealth services in store | Patients seeking convenient primary care | Pilot launched around July 2024; 4 stores at 30 June 2026 | Franchise | Counted within Priceline Pharmacy |
| Priceline Pharmacy app and online | E-commerce, click-and-collect, home delivery, medication management, e-scripts | Omnichannel shoppers | New app launched FY2026 | Retail | "Digital sales grew strongly" in FY26 (WES FY26 Results) |
| Sister Club → Pulse Rewards | Loyalty program; Pulse Rewards is a coalition across Wesfarmers Health brands | All Health customers | Sister Club: 9.6m (FY25), more than 10.4m (FY26); Pulse Rewards launched August 2026 | Free membership; points | Integrated with OnePass and Flybuys ecosystem |
| Private-label and exclusive brands | Health, vitamins, personal care, skincare and cosmetics ranges | Priceline shoppers | Ongoing | Retail | Examples include New Zealand brand Daily Skincare ranged in about 400 Priceline stores (Inside FMCG) |
| Retail media | Supplier-funded advertising across Priceline assets, linked to Group OneReach | Suppliers / brands | Scaling FY2025–FY2027 | Advertising fees | — |
| Health Check program | In-store health screening; reported links to Latrobe Health Services and SiSU stations | Pharmacy customers | Reported August 2026 | Free/partner-funded | Details only partially reported (Pharmacy Daily, 19 Aug 2026) |
Consumer — MediAesthetics
| Offering | Description | Target customer | Launch / latest | Pricing | Notes |
|---|---|---|---|---|---|
| SILK Laser Clinics | Laser hair removal, skin treatments and cosmetic injectables; company-owned, franchise and JV clinics | Aesthetics consumers (predominantly women, 20–50) | Acquired 2023 | Per-treatment, packages, memberships | Part of 180 clinics at 30 June 2026 |
| Clear Skincare Clinics | Laser, skin and injectables clinics | Mass-market aesthetics consumers | Acquired by API c.FY2018/19; FY19 revenue A$45.6m | Per-treatment, memberships | Pulse Rewards materials reference "Australia Skin Clinics", which may indicate a brand refresh. This is not confirmed; the FY26 Results still name Clear Skincare |
| AestheticsRX | Premium cosmeceutical own-brand range | Clinic clients | Expanded FY2026 | Retail | Cited as a driver of profitable growth in FY26 (WES FY26 Results) |
Network trend. Clinic numbers fell from 219 (FY2024) to 192 (FY2025) to 180 (FY2026). This reflects a "simplified operating model" and closure of 12 clinics in FY2026 (WES FY26 Results).
Consumer — Digital Health
| Offering | Description | Target customer | Launch / latest | Pricing | Notes |
|---|---|---|---|---|---|
| InstantScripts | Telehealth: online doctor consults, scripts for more than 300 medicines, medical certificates, referrals | Time-poor and regional patients | Founded 2017; acquired July 2023 (approx. A$135m) | Per-consult fees | More than 1m patient interactions in the year before acquisition (Business News Australia); "growth in users and services" in FY26 |
| SiSU Health | Self-service health check stations (blood pressure, BMI and similar) in pharmacies and retail | General public | Stake increased to 60% in FY2023 | Free to user; sponsor/partner funded | Included in acquisition amortisation (WES FY26 Results) |
| Telehealth Code of Practice | Internal clinical safety and quality framework | Patients and regulators | July 2025 | Not applicable | Governance differentiator |
Wholesale
| Offering | Description | Customer | Latest | Pricing | Notes |
|---|---|---|---|---|---|
| Full-line pharmaceutical distribution | PBS and non-PBS prescription medicines, CSO supply | More than 4,000 pharmacies | Ongoing | Regulated PBS wholesale mark-up plus CSO funding share | Growth from new customers and GLP-1/high-value drugs (FY26) |
| OTC and front-of-shop supply | OTC medicines, health, beauty and general merchandise | Pharmacies | Ongoing | Trade pricing and rebates | — |
| Online B2B hub | Ordering platform with "enhanced functionality" for wholesale pharmacy customers | More than 4,000 pharmacies | — | Not applicable | Inside FMCG |
| Automated fulfilment network | Automation upgrades; new Cairns centre (FY26); Adelaide and Perth centres opening FY2027 | Internal / customers | FY2026–FY2027 | Not applicable | Lower supply-chain unit costs in FY26 |
| Franchisee financial support | Trade credit and support facilities to franchisees | Priceline franchisees | Ongoing | — | Exposure crystallised with Infinity in December 2025 |
Financial Narrative
Because API is a wholly owned subsidiary, it no longer publishes standalone statutory accounts to the market. This section presents three views:
6A: Wesfarmers Health divisional data for FY2022–FY2026, the best available proxy for API's current economics.
6B: API's last listed-era figures for FY2017–FY2021, for history.
6C: Wesfarmers Group consolidated data, for balance sheet, cash-flow and credit context, since debt and equity sit at group level.
6A. Wesfarmers Health — income statement and returns
Source: WES FY26 Results, Divisional key performance metrics.
Notes:
-
Gross profit, net income, EPS and dividends are not publicly disclosed at divisional level.
-
FY2022 and FY2023 EBIT are derived as EBITDA plus D&A; FY2025 and FY2026 EBIT are reported.
-
Margins are computed.
-
Implied capital employed is derived as EBT divided by ROC and is an analyst estimate only.
Revenue CAGR, FY2023–FY2026 (three full years): approximately 6.8%. Computed as (6,474 / 5,312)^(1/3) − 1.
Commentary.
Revenue: Growth accelerated from 5.5% in FY2025 to 9.1% in FY2026. Three drivers are cited in WES FY26 Results:
-
Priceline Pharmacy network expansion (+25 opened / −12 closed franchise stores in FY2026)
-
strong dispensary and retail growth, with headline network sales +12.7%
-
wholesale customer wins and high-value drug volumes, notably GLP-1 weight-loss medications
FY2023 revenue was flattered by more than A$300m of COVID-19 antiviral sales (Wesfarmers 2023 Annual Report, per Pharmacy Daily). This makes FY2024's 5.9% growth on an underlying basis stronger than it appears.
Profitability: EBITDA has risen in each full year, from A$124m to A$168m (+35% over three years), but margins remain razor-thin. The EBITDA margin expanded only 26 basis points between FY2023 and FY2026. The real progress is in EBT, which rose from A$45m to A$76m (+69%), as acquisition amortisation rolls off and operating leverage emerges. EBT growth (18.8%) outpaced revenue growth (9.1%) in FY2026, which is the first clear evidence of the operating leverage management has promised.
Rising lease costs: Lease interest climbed from A$5m to A$12m between FY2024 and FY2026. This reflects new fulfilment centres (Cairns) and store and clinic leases, and is a modest drag that will grow as Adelaide and Perth open.
Returns: ROC of 4.2% in FY2026 is well below Wesfarmers' cost of capital and far below Bunnings (69.2%) and Kmart (68.3%). It is the division's central strategic weakness. Implied capital employed has grown to approximately A$1.8bn through the InstantScripts, SILK, SiSU and Pharmacy 4 Less acquisitions and working capital. FY2026 inventory was deliberately raised as a contingency against Middle East supply disruption (WES FY26 Results).
Capex: Capex nearly doubled from A$38m (FY2024) to A$70m (FY2026), driven by fulfilment automation and new centres. This is consistent with the FY2027 plan to open Adelaide and Perth centres.
6A(ii). Wesfarmers Health — operating KPIs
Sources: WES FY26 Results; Pharmacy Daily for FY2025 network sales growth and Sister Club membership.
6B. API standalone — last five listed fiscal years
These figures come from mixed primary and secondary sources. Where sources conflict, the discrepancy is noted below the table.
Commentary. API's last five listed years show a business with flat revenue of about A$4.0bn and volatile, declining statutory earnings:
PBS price disclosure reforms: steadily eroded wholesale revenue per script.
COVID-19 (FY2020–FY2021): hit Priceline's high-margin cosmetics and cold-and-flu categories. Front-of-shop like-for-like sales fell almost 6% in FY2020, and company stores and the Clear Skincare clinics closed during lockdowns.
Impairments and restructuring: (A$9.4m in October 2020) pushed statutory results to a loss in FY2020 and near break-even in FY2021.
Underlying NPAT guidance for FY2020 was about A$30–31m, roughly 45% below the FY2017 peak of A$54.2m. This deterioration explains why API traded at a depressed valuation of about A$1.15 before the July 2021 approach, and why the A$1.55 offer carried a 35.4% premium.
6C. Wesfarmers Group — consolidated context
Source: WES FY26 Results, Five-year financial performance.
Net margin, ROA and net debt to equity are computed.
Group credit metrics (FY2026).
-
Debt to EBITDA (including leases, ex significant items): 1.9x, versus 1.7x in FY2025.
-
Net financial debt: A$5,295m.
-
Weighted average cost of debt: 3.75%.
-
Committed undrawn facilities: A$1,725m.
Ratios requested but not available at API/Health level. The following are not publicly disclosed for API or Wesfarmers Health and are therefore not estimated:
-
ROE and ROA for the division
-
ROIC (ROC of 4.2% is the closest proxy)
-
current ratio
-
division-level debt/equity, net debt/EBITDA and interest coverage
-
asset turnover
-
cash conversion cycle
Division-level asset turnover can be approximated as revenue divided by implied capital employed, at approximately 3.6x in FY2026 (6,474 / approx. 1,810). This is an analyst estimate.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Internal Business Details
| Internal business | Contents | Key products / services |
|---|---|---|
Consumer | Priceline (Priceline Pharmacy franchise network, company-owned Priceline and atomica stores, banner brands); MediAesthetics (SILK Laser Clinics, Clear Skincare Clinics, AestheticsRX); Digital Health (InstantScripts, SiSU Health) | Retail health and beauty, dispensary support, clinic treatments, telehealth, health checks, loyalty, retail media |
Wholesale (Pharmaceutical Wholesale) | API's national pharmaceutical distribution operation and fulfilment centre network | PBS and non-PBS medicines, OTC and front-of-shop supply to more than 4,000 pharmacy customers; CSO supply |
Revenue by Segment and Segment Assets & Liabilities
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Wesfarmers Health revenue (AUD Mn) | 1,240 | 5,312 | 5,624 | 5,933 | 6,474 |
Wesfarmers Health EBITDA (AUD Mn) | -2 | 124 | 133 | 150 | 168 |
Wesfarmers Health EBT (AUD Mn) | -25 | 45 | 50 | 64 | 76 |
Wesfarmers Health EBT ex-PPA amortisation (AUD Mn) | — | — | 70 | 82 | 92 |
Wesfarmers Health EBT margin (%) | — | 0.8 | 0.9 | 1.1 | 1.2 |
Revenue growth YoY (%) | — | — | 5.9 | 5.5 | 9.1 |
Health share of Wesfarmers divisional revenue (%) | 3.4 | 12.2 | 12.7 | 13.0 | 13.7 |
Revenue by Segment
| Metric | 1H FY2025 | 2H FY2025 | 1H FY2026 | 2H FY2026 |
|---|---|---|---|---|
Health revenue (AUD Mn) | 3,022 | 2,911 | 3,276 | 3,198 |
Health EBT (AUD Mn) | 28 | 36 | 38 | 38 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 1,240 | 5,312 | 5,624 | 5,933 | 6,474 |
EBITDA (AUD Mn) | -2 | 124 | 133 | 150 | 168 |
Depreciation and amortisation (AUD Mn) | -22 | -74 | -78 | -78 | -80 |
EBIT (AUD Mn) | -24 | 50 | 55 | 72 | 88 |
Interest on lease liabilities (AUD Mn) | -1 | -5 | -5 | -8 | -12 |
EBT (AUD Mn) | -25 | 45 | 50 | 64 | 76 |
Acquisition PPA amortisation included (AUD Mn) | — | — | 20 | 18 | 16 |
EBT ex-PPA (AUD Mn) | — | — | 70 | 82 | 92 |
EBITDA margin (%) | — | 2.33 | 2.36 | 2.53 | 2.59 |
EBIT margin (%) | — | 0.94 | 0.98 | 1.21 | 1.36 |
EBT margin (%) | — | 0.8 | 0.9 | 1.1 | 1.2 |
Return on capital R12 (%) | — | 4.2 | 3.2 | 3.8 | 4.2 |
Capital expenditure, cash basis (AUD Mn) | 3 | 41 | 38 | 62 | 70 |
Implied capital employed (AUD Mn) | — | 1,071 | 1,563 | 1,684 | 1,810 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansOperating Metrics (count) and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Priceline company-owned stores (count) | 89 | 76 | 71 | 68 | 67 |
Priceline Pharmacy franchise stores (count) | 376 | 390 | 407 | 419 | 433 |
Banner brand pharmacies (count) | 92 | 96 | 99 | 161 | 152 |
MediAesthetics clinics (count) | 95 | 92 | 219 | 192 | 180 |
Total Health network (count) | 652 | 654 | 796 | 840 | 832 |
Priceline Pharmacy headline network sales growth (%) | — | — | — | 11.9 | 12.7 |
Sister Club members (millions) | — | — | — | 9.6 | 10.4 |
Safety TRIFR R12 | — | 6.6 | 4.6 | 4.6 | 4.0 |
Scope 1 and 2 market-based emissions (ktCO2e) | 13.8 | 11.6 | 10.9 | 9.0 | 5.3 |
Income Statement and Operating Metrics (count)
| Metric | FY2017 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|
Revenue (AUD Mn) | 4,040 | 4,000 | 4,000 | 4,010 |
Underlying EBITDA (AUD Mn) | 120.5 | — | — | — |
Reported EBITDA (AUD Mn) | 117.9 | — | — | — |
Reported or underlying EBIT (AUD Mn) | — | 94 | 56.3 | — |
Underlying NPAT (AUD Mn) | 54.2 | — | — | — |
Statutory NPAT (AUD Mn) | — | 56.6 | -7.9 | 1.4 |
Total assets (AUD Mn) | — | — | 1,540 | 1,529.9 |
Total liabilities (AUD Mn) | — | — | 1,089.1 | 1,091.1 |
Total equity (AUD Mn) | — | — | 450.9 | 438.8 |
Operating cash flow (AUD Mn) | — | — | 215.5 | 71.8 |
Priceline Pharmacy network stores (count) | 462 | — | — | — |
Priceline total network sales (AUD Mn) | — | 2,200 | 2,000 | — |
Cash Flow and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Group revenue (AUD Mn) | 36,838 | 43,550 | 44,189 | 45,700 | 47,274 |
Group EBIT after lease interest (AUD Mn) | 3,416 | 3,644 | 3,753 | 4,210 | 4,184 |
Group NPAT (AUD Mn) | 2,352 | 2,465 | 2,557 | 2,926 | 2,874 |
Group NPAT ex significant items (AUD Mn) | 2,352 | 2,465 | 2,557 | 2,653 | 2,874 |
Basic EPS (A$ cents) | 207.8 | 217.8 | 225.7 | 258.0 | 253.4 |
Ordinary DPS (A$ cents) | 180 | 191 | 198 | 206 | 222 |
Net margin (%) | 6.38 | 5.66 | 5.79 | 6.40 | 6.08 |
Total assets (AUD Mn) | 27,286 | 26,546 | 27,309 | 27,981 | 28,884 |
Total liabilities (AUD Mn) | 19,305 | 18,265 | 18,724 | 18,792 | 20,907 |
Net assets / equity (AUD Mn) | 7,981 | 8,281 | 8,585 | 9,189 | 7,977 |
Net debt (AUD Mn) | 4,491 | 4,009 | 4,272 | 4,326 | 5,271 |
Operating cash flow (AUD Mn) | 2,301 | 4,179 | 4,594 | 4,568 | 4,272 |
Net capital expenditure (AUD Mn) | 884 | 1,183 | 1,044 | 1,099 | 779 |
Free cash flow (AUD Mn) | 1,110 | 3,627 | 3,225 | 3,446 | 3,992 |
Return on equity R12 (%) | 29.4 | 31.4 | 31.3 | 34.3 | 35.5 |
ROA, NPAT / total assets (%) | 8.62 | 9.29 | 9.36 | 10.46 | 9.95 |
Net debt to equity (x) | 0.56 | 0.48 | 0.50 | 0.47 | 0.66 |
Cash realisation ratio ex significant items (%) | 59 | 100 | 105 | 102 | 91 |
Revenue by Region and Revenue by Region (%)
| Metric | FY2020 | FY2021 |
|---|---|---|
API New Zealand segment revenue (AUD Mn) | 47.7 | 42.9 |
API Australia share of revenue (%) | 98.8 | 98.9 |
Capital Markets
| Item | Detail |
|---|---|
Last traded price | A$1.53 (suspension, 22 March 2022) |
Takeover consideration | A$1.55 per share (A$1.50 cash plus A$0.05 dividends) |
Premium | 35.4% to the 9 July 2021 close; 36.8% to the 1-month VWAP |
Total consideration | A$774m |
Implied EV/Sales | approx. 0.2x FY2021 revenue of A$4.01bn (equity basis; analyst estimate) |
Valuation Snapshot
| Metric | Value | Source / basis |
|---|---|---|
Share price (early October 2026) | approx. A$76.5 | Derived from Motley Fool (most optimistic target of A$88.80 implies about 16% upside) |
5-year share price change | approx. +40% | Motley Fool, October 2026 |
Market capitalisation | approx. A$87bn | Derived |
P/E (FY26 EPS of 253.4c) | approx. 30x | Derived |
P/B | approx. 10.9x | Derived (net assets A$7,977m) |
EV/Sales | approx. 1.9x | Derived (net financial debt A$5.3bn; excludes leases) |
Analyst consensus | Average target A$77.69 (11 analysts) | Motley Fool, October 2026 |
FY26 ordinary dividend | 222c fully franked (interim 102c, final 120c paid 7 October 2026) | WES FY26 Results |
FY26 special distribution | A$1.50/share (110c capital return plus 40c special dividend) | WES FY26 Results |
Dividend yield | approx. 2.9% | Derived |
Credit ratings | Moody's A3 (stable); S&P A- (stable); S&P downside threshold raised to 3.0x debt/EBITDA in July 2026 | WES FY26 Results |
Buybacks | No active authorisation verified | Not applicable |
Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Ordinary DPS (A$ cents) | 180 | 191 | 198 | 206 | 222 |
Basic EPS (A$ cents) | 207.8 | 217.8 | 225.7 | 258.0 | 253.4 |
Analyst Conclusions
Management guidance
Wesfarmers expects Health to "continue improving earnings" by:
-
executing its transformation program
-
accelerating the higher-margin Consumer business
-
building on Wholesale improvements
-
opening the Adelaide and Perth fulfilment centres in FY2027
-
leveraging Pulse Rewards, retail media and new formats (WES FY26 Results)
No numerical divisional guidance is provided.
Bull case
-
Operating leverage is real. EBT grew 18.8% on revenue growth of 9.1% in FY26, and 1H FY26 earnings rose 35.7%.
-
Loyalty and data moat. More than 10.4m loyalty members, plus Group data and retail media, can lift Consumer margins.
-
Structural wholesale tailwinds. GLP-1 and high-value drug growth, combined with automation, could lift Wholesale returns.
Bear case
-
Returns are structurally low. ROC of 4.2% after four years of ownership and roughly A$1.8bn of capital employed.
-
Competitive asymmetry. The Sigma–Chemist Warehouse combination has scale, vertical integration and growth of 15.5%.
-
The franchise model carries hidden credit risk. Infinity exposed API's role as lender of last resort to franchisees.
Catalysts and monitorables (next 12 months)
-
Wesfarmers AGM (29 October 2026) and the Chair transition
-
Infinity Pharmacy Group sale outcome
-
Pulse Rewards adoption metrics
-
Adelaide and Perth fulfilment centre commissioning
-
1H FY27 results (February 2027): Health margin and ROC
-
PBS and CSO policy changes
-
Any disclosure of the Consumer/Wholesale segment split
Analyst verdict
Australian Pharmaceutical Industries, the ASX-listed wholesaler and Priceline franchisor, ceased to exist as a public company in April 2022. Its business, however, is larger and more strategically important than ever as the engine of Wesfarmers Health.
Under Wesfarmers, API has been rebuilt from a stagnating A$4bn distributor, whose statutory earnings collapsed to near zero in FY2020–21, into a A$6.5bn multi-format health platform spanning pharmacy, aesthetics, telehealth and loyalty. The FY2026 result was the most convincing since the acquisition:
-
revenue up 9.1%
-
EBT up 18.8% to A$76m (A$92m before acquisition amortisation)
-
Priceline Pharmacy network sales up 12.7%
-
loyalty membership above 10 million
The central issue has not changed: economics. An EBT margin of 1.2% and ROC of 4.2% sit far below Wesfarmers' hurdle rates and well below its retail divisions. Wesfarmers has invested heavily in this platform, through the A$774m purchase price, InstantScripts, SILK, SiSU, Pharmacy 4 Less and automated fulfilment. That investment will only be vindicated if Consumer earnings scale faster than Wholesale's low-margin revenue.
The Infinity receivership was a salutary reminder that the franchise model concentrates risk on API's balance sheet. The Sigma–Chemist Warehouse merger has also created a competitor with roughly 1.7 times the revenue and an integrated discount retail engine.
On balance, the trajectory is positive. Momentum is building, management execution is improving, and the parent's balance sheet provides patient capital. But the division remains a "show-me" story. The key test over the next 12–24 months is whether ROC can move decisively toward double digits as new fulfilment capacity, Pulse Rewards and formats like atomica mature.
For Wesfarmers shareholders, Health is not yet a material earnings contributor, at about 2% of divisional earnings. Its significance is optionality, not current value.
Verdict: improving fundamentals, low returns, monitor for margin inflection.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Compensation |
|---|---|---|---|
Emily Amos | Managing Director, Wesfarmers Health | Led the division since its formation in 2022; named MD in June 2023 releases and the FY26 results presentation | Not individually disclosed (not a Wesfarmers KMP in sources reviewed) |
Richard Pearson | Chief Customer Officer, Wesfarmers Health | Named in June 2025 (Pharmacy 4 Less) and December 2025 (Infinity) communications | — |
Corrina Brazel | — | Profiled by Inside FMCG | — |
Amanda Lean | General Manager, Corporate Affairs & Sustainability | Named in 2023 release | — |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Notes |
|---|---|---|
Michael Chaney AO | Chairman (since November 2015) | Retiring at the conclusion of the 2026 AGM (29 October 2026). Former Wesfarmers MD 1992–2005 (Wesfarmers ASX release, 28 August 2025) |
Ken MacKenzie | Non-executive director from 1 June 2026; Chair-designate | Former Chairman of BHP Group and CEO of Amcor; stands for election at the 2026 AGM |
Rob Scott | Managing Director and CEO | Presented FY2026 results |
Sharon Warburton | Non-executive director | Directors' share plan acquisitions, February 2026 |
Alan Cransberg | Non-executive director | Directors' share plan acquisitions, February 2026 |
Rt Hon Simon (Bill) English | Non-executive director | Share issue, March 2026 |
Friedrich (Tom) Oertzen | Disclosed in directors' trading (buy, March 2026) | — |
Other directors | Not fully verified in this research | Refer to the Wesfarmers 2026 Annual Report |
Board & Management Changes
| Date | Event |
|---|---|
28 Aug 2025 | Chair succession announced: Chaney to retire at the 2026 AGM; Ken MacKenzie named successor |
1 Jun 2026 | MacKenzie joined the board |
29 Oct 2026 (scheduled) | AGM; MacKenzie assumes chair |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Ownership | Notes |
|---|---|---|---|
Wholesale | Sigma Healthcare (incl. Chemist Warehouse) | ASX: SIG | FY26 revenue A$10.8bn (+15.5%), first full year post-merger (Pharmacy Daily) |
Wholesale | Symbion (EBOS Group) | ASX/NZX: EBO | EBOS FY26 revenue 13.5bn (+9.9%), underlying profit 614m, as reported (reporting currency per EBOS) |
Wholesale | CH2 (Clifford Hallam Healthcare) | Private | Secondary full-line wholesaler; financials not disclosed |
Wholesale | Independent Pharmacy Cooperative and regional wholesalers | Private | Niche |
Pharmacy retail | Chemist Warehouse | Sigma | Discount market leader |
Pharmacy retail | TerryWhite Chemmart | EBOS | Claims more than one-third share of pharmacist prescribing (AJP) |
Pharmacy retail | Amcal / Guardian / Discount Drug Stores | Sigma (banners) | Banner competitors |
Pharmacy retail | Blooms The Chemist, National Pharmacies, Good Price Pharmacy | Various | National Pharmacies won Canstar's 2026 satisfaction award |
Beauty retail | Mecca, Sephora (LVMH), Adore Beauty, Woolworths/Coles beauty aisles | Various | Compete with Priceline/atomica front of shop |
Aesthetics | Laser Clinics Australia; independent clinics | Private | Compete with SILK/Clear Skincare |
Telehealth | Eucalyptus (Juniper, Pilot), Doctors on Demand, other platforms | Private | Compete with InstantScripts |
Peer Comparison FY2026
| Metric | Wesfarmers Health (API) | Sigma Healthcare | EBOS Group | Chemist Warehouse (within Sigma) |
|---|---|---|---|---|
Revenue | A$6.47bn (FY26) | A$10.8bn (FY26) | 13.5bn (FY26, as reported) | Consolidated in Sigma |
Revenue growth | +9.1% | +15.5% | +9.9% | Not applicable |
Profit measure | EBT A$76m (1.2% margin) | — | Underlying profit 614m | Not applicable |
Recent Developments
--



